Manufacturers’ Life Insurance Company said in its latest 13F file filed with the U.S. Securities and Exchange Commission (SEC) that it cut its stake in Qiagen (NYSE:QGEN – Get Rating) by 5.2% in the third quarter. I’m here. The institutional investor owned his 96,492 shares of the company’s stock after selling his 5,302 shares during the period. His holdings in Qiagen, a manufacturer’s life insurance company, were valued at $4,071,000 at the end of the most recent reporting period.
Many other hedge funds and other institutional investors also buy and sell stocks. Captrust Financial Advisors increased its stake in Qiagen by 23.1% in the first quarter. Captrust Financial Advisors now owns 1,232 of his shares worth $60,000 after purchasing an additional 231 of his shares last quarter. Cigna Investments Inc. New increased its stake in Qiagen by 7.5% in the second quarter. Cigna Investments Inc. New now owns 4,495 shares worth $210,000 after purchasing an additional 312 shares last quarter. Bridgewater Associates LP increased Qiagen’s stake by 1.0% in the second quarter. Bridgewater Associates LP now owns 46,043 shares worth $2,173,000 after purchasing an additional 451 shares last quarter. CWM LLC increased its stake in Qiagen by 314.4% in the third quarter. CWM LLC now owns 866 shares of the company, valued at $36,000, after purchasing an additional 657 shares in the previous quarter. Finally, Toroso Investments LLC increased its stake in Qiagen by 11.0% in the first quarter. Toroso Investments LLC now owns 7,392 shares worth $362,000 after purchasing an additional 735 shares last quarter. Hedge funds and other institutional investors own 58.62% of the company’s shares.
Qiagen stock up 0.4%
NYSE QGEN shares opened Wednesday at $49.00. The company has a current ratio of 1.84, a quick ratio of 1.62 and a debt to equity ratio of 0.43. His 12-month low on Qiagen is $40.38 and his 12-month high is $51.30. The company has a market capitalization of $11.13 billion, a PE ratio of 24.38, a P/E ratio of 1.35 and a beta of 0.41. The company has a 50-day simple moving average of $49.70 and a 200-day simple moving average of $46.56.
Qiagen (NYSE:QGEN – Get Rating) last reported quarterly results on Monday, November 7. The company reported his earnings per share (EPS) of $0.53 for the quarter, $0.08 above analyst consensus expectations of $0.45 for him. Qiagen’s net profit margin was 20.83% and return on equity was 18.43%. The company posted revenue of $499.63 million for the quarter, compared with analysts’ forecast of $479.99 million. Equity analysts expect Qiagen to post his 2.32 earnings per share this year.
Wall Street analyst opinion
QGEN has been the subject of many research reports. Citigroup lowered its price target on Qiagen shares from $62.00 to $55.00, setting a “buy” rating for the company in his Wednesday, November 9 research note. Berenberg Bank increased its price target for Qiagen shares from €53.91 ($58.60) to €54.60 ($59.35) in a research note on Friday, November 11. Morgan Stanley began covering her Qiagen shares in a research note on Tuesday, Oct. 18. They issued an “equal-weighted” rating to the company. Oddo Bhf downgraded Qiagen’s shares from ‘outperforming’ to ‘neutral’ in a research note on Monday 10 October. Finally, StockNews.com kicked off his coverage of Qiagen shares in his Wednesday Oct. 12 report. They set a “buy” rating for the company. Three Research-his analysts rated the stock with a hold rating, and two assigned a buy-his rating to the company’s shares. Based on MarketBeat data, the company has an average rating of “pending” and an average target price of $54.80.
Qiagen Profile
(get rating)
QIAGEN NV provides sample-to-insight solutions worldwide that transform biological materials into molecular insights. The company offers nuclear stabilization and purification kits for primary sample material, manual and automated processing for genotyping, gene expression, viral and bacterial analysis, and consumables for primary sample technology such as silica membrane and magnetic bead technology. I’m here. Secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample material. Instruments for nucleic acid purification and accessories.
Featured Stories
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to contact@marketbeat.com.
You’ll want to hear this before considering Qiagen.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat identified five stocks top analysts are quietly whispering to customers to buy now before the broader market takes notice…and Qiagen wasn’t on the list.
Qiagen currently has a ‘Hold’ rating among analysts, but top-rated analysts believe these five stocks are better buys.
See 5 stocks here
